| Literature DB >> 31011579 |
Maryam Mukhtar1, Nadeem Sheikh1, Saira Kainat Suqaina1, Andleeb Batool2, Naz Fatima1, Rabia Mehmood1, Sabeen Nazir1.
Abstract
Vitamin D is an anti-inflammatory molecule and has a role in prevention of arthritis development. Biologically active form 1, 25(OH)2D3 of vitamin D can only exert its action after binding its definite vitamin D receptor encoded by VDR gene. VDR gene polymorphism leads to dysfunctioning of 1, 25(OH)2D3 ultimately disease onset. The purpose of current study was to evaluate the effect of vitamin D level and VDR gene polymorphism on rheumatoid arthritis and osteoarthritis. Blood samples were collected from case and control after taking written consent. Serum was separated and vitamin D level as determined from each sample by ELISA. DNA was extracted from each blood sample and amplified by using gene specific primers. Genotyping was performed by Sangers sequencing and PCR-RFLP technique. It was found that vitamin D level was not significantly different among patients and controls. The rs10735810, rs1544410, rs7975232, and rs731236 were associated with the onset of arthritis at both allelic and genotypic level (p < 0.01). Nucleotide change on rs10735810 site leads to change of tryptophan with arginine. The frequencies of haplotype CGAT, CGGA, CGGT, CTAA, CTAT, TGAA, TGAT, TGGA, and TTGA were higher in patients and act as risk factors of RA onset, whereas haplotypes CGAT, CGAT, CGGT, CTGA, TGAT, TGGA, TTAA, and TTGA were associated with OA onset. In conclusion, serum vitamin D level may be normal among arthritis patients but polymorphism on VDR gene restricts vitamin D to perform its anti-inflammatory function by altering the 1, 25(OH)2 D3 binding sites.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31011579 PMCID: PMC6442488 DOI: 10.1155/2019/8326246
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Clinical Characteristics of participitants.
| Sr No. | Parameters | RA (n=300) | OA (n=316) | ||
|---|---|---|---|---|---|
| Males (n=71) | Females (n=229) | Males (n=100) | Females (n=216) | ||
| 1. | Age (Years) | 38.62 (35.94 ± 41.30) | 38.98 (37.42 ± 40.55) | 55.27 (52.88 ± 57.66) | 49.19 (47.79 ± 50.58) |
| 2. | BMI (Kg/m2) | 24.56 (23.45 ± 25.68) | 26.43 (25.70 ± 27.16) | 30.40 (29.20 ± 31.61) | 30.00 (29.32 ± 30.69) |
| 3. | Age of Diagnosis (Years) | 33.06 (30.55 ± 35.56) | 31.56 (29.97 ± 33.15) | 46.95 (44.84 ± 49.06) | 42.73 (40.61 ± 44.85) |
| 4. | Disease Duration (Years) | 5.83 (4.436 ± 7.223) | 7.27 (6.464 ± 8.075) | 7.06 (5.690 ± 8.436) | 5.64 (4.985 ± 6.295) |
| 5. | Positive Family History (%) | 85.92 | 80.35 | 69.00 | 68.98 |
BMI = Body Mass Index; n = No of individuals; RA = Rheumatoid arthritis; OA = Osteoarthritis.
Figure 1Comparison of serum vitamin D level among RA, OA, and controls.
Allelic test of genetic variants in RA, OA and controls.
| SNPs | Alleles | RA |
| p-value | OA |
| p-value |
|---|---|---|---|---|---|---|---|
| rs10735810 | C | 0.723/0.018 | 799.60 | 0.016 | 0.671/0.018 | 723.47 | 0.016 |
| T | 0.277/0.982 | 0.329/0.982 | |||||
|
| |||||||
| rs7975232 | G | 0.745/0.001 | 890.75 | 0.016 | 0.628/0.001 | 707.78 | 0.015 |
| T | 0.255/0.999 | 0.372.0.999 | |||||
|
| |||||||
| rs1544410 | A | 0.803/0.000 | 1000.64 | >0.01 | 0.233/0.000 | 213.18 | 0.016 |
| G | 0.197/1.000 | 0.767/1.000 | |||||
|
| |||||||
| rs731236 | A | 0.315/0.000 | 299.28 | 0.015 | 0.489/0.000 | 511.40 | 0.016 |
| T | 0.685/1.000 | 0.511/1.000 | |||||
P= Patients; C= Control; ∗ represents significance at the 0.01 level.
Genetic test of genetic variants in RA, OA and controls.
| SNPs | Genotypes | RA |
| p-value | OA |
| p-value |
|---|---|---|---|---|---|---|---|
| rs10735810 | CC | 0.537/0.000 | 554.05 | 0.016 | 0.345/0.000 | 667.02 | 0.017 |
| CT | 0.373/0.036 | 0.652/0.036 | |||||
| TT | 0.090/0.964 | 0.003/0.964 | |||||
|
| |||||||
| rs7975232 | GG | 0.530/0.000 | 660.108 | 0.016 | 0.278/0.000 | 695.92 | >0.01 |
| GT | 0.430/0.002 | 0.699/0.002 | |||||
| TT | 0.040/0.998 | 0.022/0.988 | |||||
|
| |||||||
| rs1544410 | AA | 0.697/0.000 | 608.07 | 0.008 | 0.098/0.000 | 179.90 | 0.005 |
| AG | 0.213/0.000 | 0.269/0.000 | |||||
| GG | 0.090/1.000 | 0.633/1.000 | |||||
|
| |||||||
| rs731236 | AA | 0.050/0.000 | 316.24 | 0.005 | 0.000/0.000 | 699.98 | 0.015 |
| AT | 0.530/0.000 | 0.978/0.000 | |||||
| TT | 0.420/1.000 | 0.022/1.000 | |||||
P= Patients; C= Control; ∗ represents significance at the 0.01 level.
Regression analysis (Studied SNP's association with response Status (n=712, adjusted by Sex+Age+BMI).
| SNPs | Model | Genotype | RA | OA | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Status=Cases | Status=Control | P-value | AIC | BIC | Status= | Status= | P-value | AIC | BIC | |||
| rs10735810 | Dominant | T/T | 27 (9%) | 397 (96.4%) | <0.0001 | 321.7 | 344.5 | 1 (0.3%) | 397 (96.4%) | <0.0001 | 132.1 | 159.5 |
| C/T-C/C | 273 (91%) | 15 (3.6%) | 309 (99.7%) | 15 (3.6%) | ||||||||
| Recessive | T/T-C/T | 139 (46.3%) | 412 (100%) | <0.0001 | 611.4 | 634.3 | 204 (65.8%) | 412 (100%) | <0.0001 | 702.8 | 730.3 | |
| C/C | 161 (53.7%) | 0 (0%) | 106 (34.2%) | 0 (0%) | ||||||||
|
| ||||||||||||
| rs7975232 | Dominant | T/T | 12 (4%) | 411 (99.8%) | <0.0001 | 123.3 | 146.1 | 6 (1.9%) | 411 (99.8%) | <0.0001 | 52.7 | 80.2 |
| G/T-G/G | 288 (96%) | 1 (0.2%) | 304 (98.1%) | 1 (0.2%) | ||||||||
| Recessive | T/T-G/T | 141 (47%) | 412 (100%) | <0.0001 | 637 | 659.8 | 227 (73.2%) | 412 (100%) | <0.0001 | 735.8 | 763.3 | |
| G/G | 159 (53%) | 0 (0%) | 83 (26.8%) | 0 (0%) | ||||||||
|
| ||||||||||||
| rs1544410 | Dominant | G/G | 27 (9%) | 412 (100%) | <0.0001 | 208.8 | 231.7 | 194 (62.6%) | 412 (100%) | <0.0001 | 562.5 | 590 |
| A/G-A/A | 273 (91%) | 0 (0%) | 116 (37.4%) | 0 (0%) | ||||||||
| Recessive | G/G-A/G | 91 (30.3%) | 412 (100%) | <0.0001 | 484.6 | 507.5 | 79 (90%) | 412 (100%) | <0.0001 | 771 | 798.5 | |
| A/A | 209 (69.7%) | 0 (0%) | 31 (10%) | 0 (0%) | ||||||||
|
| ||||||||||||
| rs731236 | Dominant | T/T | 126 (42%) | 412 (100%) | <0.0001 | 510.6 | 533.4 | - | - | - | - | - |
| A/T-A/A | 174 (58%) | 0 (0%) | - | - | ||||||||
| Recessive | T/T-A/T | 285 (95%) | 412 (100%) | <0.0001 | 947 | 969.8 | - | - | - | - | - | |
| A/A | 15 (5%) | 0 (0%) | - | - | ||||||||
AIC=Akaike information criterion; BIC=Bayesian information criterion; P-value<0.01=significant.
Haplotype Analysis of the VDR gene located on chromosome 12.
| Haplotype: rs10735810; rs7975232; rs1544410; rs731236 | |||||
|---|---|---|---|---|---|
| Haplotype | RA | p-value | Haplotype | OA | p-value |
|
| |||||
| CTGT | 0.030/0.018 | 0.140 | CTGT | 0.015/0.018 | 0.651 |
| TGGT | 0.021/0.001 | 0.001 | TGGT | 0.004/0.001 | 0.001 |
| TTGT | 0.002/0.981 | 0.001 | TTGT | 0.000/0.981 | 0.016 |
| CGAT | 0.301/0.000 | 0.016 | CGAT | 0.102/0.000 | 0.016 |
| CGGA | 0.071/0.000 | 0.014 | CGGA | 0.088/0.000 | 0.015 |
| CGGT | 0.041/0.000 | 0.009 | CGGT | 0.379/0.000 | 0.016 |
| CTAA | 0.011/0.000 | 0.002 | CTAA | 0.001/0.000 | >0.01 |
| CTAT | 0.188/0.000 | 0.016 | CTGA | 0.086/0.000 | 0.015 |
| TGAA | 0.120/0.000 | 0.015 | TGAT | 0.011/0.000 | 0.002 |
| TGAT | 0.102/0.000 | 0.015 | TGGA | 0.044/0.000 | 0.001 |
| TGGA | 0.007/0.000 | 0.001 | TTAA | 0.118/0.000 | 0.001 |
| TTGA | 0.026/0.000 | 0.006 | TTGA | 0.152/0.000 | 0.001 |
∗Represents a significant association of Haplotypes with Arthritis onset.
۞ Represents a significant association of Haplotypes protective against Arthritis onset.
Figure 2Location and map of linkage disequilibrium (LD) in SNPs at VDR gene in RA are presented. The SNPs numbers are indicated at the top of haploview. (a) LD = D/ (b) LD coefficient.
Figure 3Location and map of linkage disequilibrium (LD) in SNPs at VDR gene in OA are presented. The SNPs numbers are indicated at the top of haploview. (a) LD = D/ (b) LD coefficient.